Distinct effects of saracatinib on memory CD8 + T cell differentiation

Journal of Immunology

Volumn 188, Issue 9, 2012, Pages 4323-4333

  Takai, Shinji ^a   Sabzevari, Helen ^a,b   Farsaci, Benedetto ^a   Schlom, Jeffrey ^a   Greiner, John W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b EMD Serono   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; DASATINIB; GAMMA INTERFERON; HERMES ANTIGEN; INFLUENZA VACCINE; INTERLEUKIN 2; L SELECTIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN KINASE FYN; PROTEIN KINASE LCK; PROTEIN TYROSINE KINASE; RECOMBINANT VACCINE; S6 KINASE; SARACATINIB; T LYMPHOCYTE RECEPTOR; VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; IN VITRO STUDY; INNATE IMMUNITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD44; ANTIGENS, VIRAL; BENZODIOXOLES; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; HUMANS; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS; INFLUENZA VACCINES; INTERFERON-GAMMA; L-SELECTIN; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; QUINAZOLINES; SRC-FAMILY KINASES; VIRAL PROTEINS;

EID: 84860340932     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101439     Document Type: Article

References (50)

1. Nowak, A. K., B. W. Robinson, and R. A. Lake. 2002. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res. 62: 2353-2358. (Pubitemid 34411717)
2. Vincent, J., G. Mignot, F. Chalmin, S. Ladoire, M. Bruchard, A. Chevriaux, F. Martin, L. Apetoh, C. Rébé, and F. Ghiringhelli. 2010. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70: 3052-3061.
3. Araki, K., A. P. Turner, V. O. Shaffer, S. Gangappa, S. A. Keller, M. F. Bachmann, C. P. Larsen, and R. Ahmed. 2009. mTOR regulates memory CD8 T-cell differentiation. Nature 460: 108-112.
4. Pearce, E. L., M. C. Walsh, P. J. Cejas, G. M. Harms, H. Shen, L. S. Wang, R. G. Jones, and Y. Choi. 2009. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460: 103-107.
5. Farsaci, B., H. Sabzevari, J. P. Higgins, M. G. Di Bari, S. Takai, J. Schlom, and J. W. Hodge. 2010. Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine. Int. J. Cancer 127: 1603-1613.
6. Klebanoff, C. A., L. Gattinoni, and N. P. Restifo. 2006. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211: 214-224 (Review). (Pubitemid 43882974)
7. Williams, M. A., and M. J. Bevan. 2007. Effector and memory CTL differentiation. Annu. Rev. Immunol. 25: 171-192 (Review). (Pubitemid 46697906)
8. Sarkar, S., V. Teichgräber, V. Kalia, A. Polley, D. Masopust, L. E. Harrington, R. Ahmed, and E. J. Wherry. 2007. Strength of stimulus and clonal competition impact the rate of memory CD8 T cell differentiation. J. Immunol. 179: 6704-6714.
9. Vezys, V., A. Yates, K. A. Casey, G. Lanier, R. Ahmed, R. Antia, and D. Masopust. 2009. Memory CD8 T-cell compartment grows in size with immunological experience. Nature 457: 196-199.
10. Laouar, A., M. Manocha, V. Haridas, and N. Manjunath. 2008. Concurrent generation of effector and central memory CD8 T cells during vaccinia virus infection. PLoS ONE 3: e4089.
11. Gattinoni, L., C. A. Klebanoff, and N. P. Restifo. 2009. Pharmacologic induction of CD8+ T cell memory: better living through chemistry. Sci. Transl. Med. 1: 11ps12.
12. Schenone, S., C. Brullo, F. Musumeci, and M. Botta. 2010. Novel dual Src/Abl inhibitors for hematologic and solid malignancies. Expert Opin. Investig. Drugs 19: 931-945 (Review).
13. Green, T. P., M. Fennell, R. Whittaker, J. Curwen, V. Jacobs, J. Allen, A. Logie, J. Hargreaves, D. M. Hickinson, R. W. Wilkinson, et al. 2009. Preclinical anti-cancer activity of the potent, oral Src inhibitor AZD0530. Mol. Oncol. 3: 248-261.
14. Hennequin, L. F., J. Allen, J. Breed, J. Curwen, M. Fennell, T. P. Green, C. Lambert-van der Brempt, R. Morgentin, R. A. Norman, A. Olivier, et al. 2006. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J. Med. Chem. 49: 6465-6488. (Pubitemid 44657442)
15. Lombardo, L. J., F. Y. Lee, P. Chen, D. Norris, J. C. Barrish, K. Behnia, S. Castaneda, L. A. Cornelius, J. Das, A. M. Doweyko, et al. 2004. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2- methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47: 6658-6661. (Pubitemid 40053752)
16. Trevino, J. G., J. M. Summy, and G. E. Gallick. 2006. SRC inhibitors as potential therapeutic agents for human cancers. Mini Rev. Med. Chem. 6: 681-687. (Pubitemid 43881119)
17. Palacios, E. H., and A. Weiss. 2004. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 23: 7990-8000 (Review). (Pubitemid 39468856)
18. Weichsel, R., C. Dix, L. Wooldridge, M. Clement, A. Fenton-May, A. K. Sewell, J. Zezula, E. Greiner, E. Gostick, D. A. Price, et al. 2008. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin. Cancer Res. 14: 2484-2491. (Pubitemid 351551084)
19. Fraser, C. K., S. J. Blake, K. R. Diener, A. B. Lyons, M. P. Brown, T. P. Hughes, and J. D. Hayball. 2009. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp. Hematol. 37: 256-265.
20. Townsend, A. R., J. Rothbard, F. M. Gotch, G. Bahadur, D. Wraith, and A. J. McMichael. 1986. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44: 959-968. (Pubitemid 16045342)
21. Mamalaki, C., J. Elliott, T. Norton, N. Yannoutsos, A. R. Townsend, P. Chandler, E. Simpson, and D. Kioussis. 1993. Positive and negative selection in transgenic mice expressing a T-cell receptor specific for influenza nucleoprotein and endogenous superantigen. Dev. Immunol. 3: 159-174.
22. Clarke, P., J. Mann, J. F. Simpson, K. Rickard-Dickson, and F. J. Primus. 1998. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res. 58: 1469-1477. (Pubitemid 28193610)
23. Schmitz, J., E. Reali, J. W. Hodge, A. Patel, G. Davis, J. Schlom, and J. W. Greiner. 2002. Identification of an interferon-γ-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res. 62: 5058-5064. (Pubitemid 34984434)
24. Robbins, P. F., J. A. Kantor, M. Salgaller, P. H. Hand, P. D. Fernsten, and J. Schlom. 1991. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res. 51: 3657-3662.
25. Litzinger, M. T., R. Fernando, T. J. Curiel, D. W. Grosenbach, J. Schlom, and C. Palena. 2007. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 110: 3192-3201. (Pubitemid 350106311)
26. Hodge, J. W., H. Sabzevari, A. G. Yafal, L. Gritz, M. G. Lorenz, and J. Schlom. 1999. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59: 5800-5807.
27. Kass, E., J. Parker, J. Schlom, and J. W. Greiner. 2000. Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen-presenting cells in regional lymph nodes. Cytokine 12: 960-971. (Pubitemid 30479478)
28. Weninger, W., M. A. Crowley, N. Manjunath, and U. H. von Andrian. 2001. Migratory properties of naive, effector, and memory CD8(+) T cells. J. Exp. Med. 194: 953-966. (Pubitemid 32953264)
29. Klebanoff, C. A., S. E. Finkelstein, D. R. Surman, M. K. Lichtman, L. Gattinoni, M. R. Theoret, N. Grewal, P. J. Spiess, P. A. Antony, D. C. Palmer, et al. 2004. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. USA 101: 1969-1974. (Pubitemid 38228999)
30. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. USA 102: 9571-9576. (Pubitemid 40981722)
31. Kaech, S. M., J. T. Tan, E. J. Wherry, B. T. Konieczny, C. D. Surh, and R. Ahmed. 2003. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4: 1191-1198. (Pubitemid 37540688)
32. Kass, E., J. Schlom, J. Thompson, F. Guadagni, P. Graziano, and J. W. Greiner. 1999. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res. 59: 676-683. (Pubitemid 29076067)
33. Baaten, B. J., C. R. Li, M. F. Deiro, M. M. Lin, P. J. Linton, and L. M. Bradley. 2010. CD44 regulates survival and memory development in Th1 cells. Immunity 32: 104-115.
34. Do, Y., P. S. Nagarkatti, and M. Nagarkatti. 2004. Role of CD44 and hyaluronic acid (HA) in activation of alloreactive and antigen-specific T cells by bone marrow-derived dendritic cells. J. Immunother. 27: 1-12. (Pubitemid 38076164)
35. Rozsnyay, Z. 1999. Signaling complex formation of CD44 with src-related kinases. Immunol. Lett. 68: 101-108. (Pubitemid 29265659)
36. Marhaba, R., P. Freyschmidt-Paul, and M. Zöller. 2006. In vivo CD44-CD49d complex formation in autoimmune disease has consequences on T cell activation and apoptosis resistance. Eur. J. Immunol. 36: 3017-3032. (Pubitemid 44782575)
37. Nakano, K., K. Saito, S. Mine, S. Matsushita, and Y. Tanaka. 2007. Engagement of CD44 up-regulates Fas ligand expression on T cells leading to activation-induced cell death. Apoptosis 12: 45-54. (Pubitemid 46009503)
38. Chang, Y. M., L. Bai, S. Liu, J. C. Yang, H. J. Kung, and C. P. Evans. 2008. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 27: 6365-6375.
39. Arcaroli, J. J., B. M. Touban, A. C. Tan, M. Varella-Garcia, R. W. Powell, S. G. Eckhardt, P. Elvin, D. Gao, and W. A. Messersmith. 2010. Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. Clin. Cancer Res. 16: 4165-4177.
40. Ammer, A. G., L. C. Kelley, K. E. Hayes, J. V. Evans, L. A. Lopez-Skinner, K. H. Martin, B. Frederick, B. L. Rothschild, D. Raben, P. Elvin, et al. 2009. Saracatinib impairs head and neck squamous cell carcinoma invasion by disrupting invadopodia function. J. Cancer Sci. Ther. 1: 52-61.
41. Bertotti, A., C. Bracco, F. Girolami, D. Torti, S. Gastaldi, F. Galimi, E. Medico, P. Elvin, P. M. Comoglio, and L. Trusolino. 2010. Inhibition of Src impairs the growth of met-addicted gastric tumors. Clin. Cancer Res. 16: 3933-3943.
42. Rajeshkumar, N. V., A. C. Tan, E. De Oliveira, C. Womack, H. Wombwell, S. Morgan, M. V. Warren, J. Walker, T. P. Green, A. Jimeno, et al. 2009. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin. Cancer Res. 15: 4138-4146.
43. Pichot, C. S., S. M. Hartig, L. Xia, C. Arvanitis, D. Monisvais, F. Y. Lee, J. A. Frost, and S. J. Corey. 2009. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br. J. Cancer 101: 38-47.
44. Jones, R. G., and C. B. Thompson. 2007. Revving the engine: signal transduction fuels T cell activation. Immunity 27: 173-178. (Pubitemid 47284920)
45. Grayson, J. M., A. J. Zajac, J. D. Altman, and R. Ahmed. 2000. Cutting edge: increased expression of Bcl-2 in antigen-specific memory CD8+ T cells. J. Immunol. 164: 3950-3954. (Pubitemid 30215046)
46. Schluns, K. S., W. C. Kieper, S. C. Jameson, and L. Lefrançois. 2000. Interleukin-7 mediates the homeostasis of nïve and memory CD8 T cells in vivo. Nat. Immunol. 1: 426-432.
47. Norbury, C. C., D. Malide, J. S. Gibbs, J. R. Bennink, and J. W. Yewdell. 2002. Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo. Nat. Immunol. 3: 265-271. (Pubitemid 34213428)
48. Wong, P., and E. G. Pamer. 2003. Feedback regulation of pathogen-specific T cell priming. Immunity 18: 499-511. (Pubitemid 36513632)
49. Huster, K. M., C. Stemberger, G. Gasteiger, W. Kastenmüller, I. Drexler, and D. H. Busch. 2009. Cutting edge: memory CD8 T cell compartment grows in size with immunological experience but nevertheless can lose function. J. Immunol. 183: 6898-6902.
50. Schade, A. E., G. L. Schieven, R. Townsend, A. M. Jankowska, V. Susulic, R. Zhang, H. Szpurka, and J. P. Maciejewski. 2008. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 111: 1366-1377. (Pubitemid 351213423)